



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10278-009001	Application No. 09/407,605
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Allan M. Miller et al.	
		Filing Date September 28, 1999	Group Art Unit 1643

U.S. Patent Documents							
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						

RECEIVED

OCT 17 2002

TECH CENTER 1600-2900

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
CHK	AG	96/09378 A1	03/28/1996	WIPO				
CHK	AH	98/12207 A1	03/26/1998	WIPO				
	AI							
	AJ							
	AK							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
CHK	AL	Peter Lind et al., "Novel forms of B-domain-deleted recombinant factor VIII molecules Construction and biochemical characterization", <u>European Journal of Biochemistry</u> , Vol. 232, No. 1, pages 19-27 (August 15, 1995)
	AM	Carmel M. Lynch et al., "Sequences in the Coding Region of Clotting Factor VIII Act as Dominant Inhibitors of RNA Accumulation and Protein Production", <u>Human Gene Therapy</u> , Vol. 4, No. 3, pages 259-272 (June 1, 1993)
CHK	AN	Louise C. Wasley et al., "PACE Furin Can Process the Vitamin K-dependent Pro-factor IX Precursor within the Secretory Pathway", <u>Journal of Biological Chemistry</u> , Vol. 268, No. 12, pages 8458-8465 (April 25, 1993)
	AO	
	AP	

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.